A RESPONSE TO 'THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER'
| Autor: | Clarissa Emy Higuchi Zerbini, Sarika Ogale, Romain Freund, Miranta Antoniou |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Second line treatment Indazoles Lung Neoplasms business.industry Health Policy Pharmaceutical Science Entrectinib Pharmacy Term (time) Pyrimidines Internal medicine Trk receptor Benzamides medicine Metastatic lung cancer Humans Pyrazoles business Protein Kinase Inhibitors |
| Zdroj: | Journal of managed carespecialty pharmacy. 26(12) |
| ISSN: | 2376-1032 |
| Popis: | DISCLOSURES: The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|